6yva › Citations

Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity.

<div class='caption-title'>DeISGylating and deubiquitylating activities of SCoV-PLpro and SCoV2-PLpro.</div>
<div class='caption-title'>Structural analysis of SARS-CoV-2 PLpro in complex with full length ISG15.</div>
<div class='caption-title'>Effect of GRL-0617 on SCoV2-PLpro.</div>
Shin D, Mukherjee R, Grewe D, Bojkova D, Baek K, Bhattacharya A, Schulz L, Widera M, Mehdipour AR, Tascher G, Geurink PP, Wilhelm A, van der Heden van Noort GJ, Ovaa H, Müller S, Knobeloch KP, Rajalingam K, Schulman BA, Cinatl J, Hummer G, Ciesek S, Dikic I
OpenAccess logo Nature 587 657-662 (2020)
Cited: 530 times
EuropePMC logo PMID: 32726803

Abstract

The papain-like protease PLpro is an essential coronavirus enzyme that is required for processing viral polyproteins to generate a functional replicase complex and enable viral spread1,2. PLpro is also implicated in cleaving proteinaceous post-translational modifications on host proteins as an evasion mechanism against host antiviral immune responses3-5. Here we perform biochemical, structural and functional characterization of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) PLpro (SCoV2-PLpro) and outline differences with SARS-CoV PLpro (SCoV-PLpro) in regulation of host interferon and NF-κB pathways. SCoV2-PLpro and SCoV-PLpro share 83% sequence identity but exhibit different host substrate preferences; SCoV2-PLpro preferentially cleaves the ubiquitin-like interferon-stimulated gene 15 protein (ISG15), whereas SCoV-PLpro predominantly targets ubiquitin chains. The crystal structure of SCoV2-PLpro in complex with ISG15 reveals distinctive interactions with the amino-terminal ubiquitin-like domain of ISG15, highlighting the high affinity and specificity of these interactions. Furthermore, upon infection, SCoV2-PLpro contributes to the cleavage of ISG15 from interferon responsive factor 3 (IRF3) and attenuates type I interferon responses. Notably, inhibition of SCoV2-PLpro with GRL-0617 impairs the virus-induced cytopathogenic effect, maintains the antiviral interferon pathway and reduces viral replication in infected cells. These results highlight a potential dual therapeutic strategy in which targeting of SCoV2-PLpro can suppress SARS-CoV-2 infection and promote antiviral immunity.

Reviews - 6yva mentioned but not cited (6)

  1. Structural Characterization of SARS-CoV-2: Where We Are, and Where We Need to Be. Mariano G, Farthing RJ, Lale-Farjat SLM, Bergeron JRC. Front Mol Biosci 7 605236 (2020)
  2. A Comprehensive Review about the Molecular Structure of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Insights into Natural Products against COVID-19. Saied EM, El-Maradny YA, Osman AA, Darwish AMG, Abo Nahas HH, Niedbała G, Piekutowska M, Abdel-Rahman MA, Balbool BA, Abdel-Azeem AM. Pharmaceutics 13 1759 (2021)
  3. Inhibitors of SARS-CoV-2 PLpro. Calleja DJ, Lessene G, Komander D. Front Chem 10 876212 (2022)
  4. An Overview of the Crystallized Structures of the SARS-CoV-2. Ionescu MI. Protein J 39 600-618 (2020)
  5. Genomics insights of SARS-CoV-2 (COVID-19) into target-based drug discovery. Chellapandi P, Saranya S. Med Chem Res 29 1777-1791 (2020)
  6. Potential Inhibitors Targeting Papain-Like Protease of SARS-CoV-2: Two Birds With One Stone. Jiang H, Yang P, Zhang J. Front Chem 10 822785 (2022)

Articles - 6yva mentioned but not cited (28)



Reviews citing this publication (210)

  1. Structural insights into SARS-CoV-2 proteins. Arya R, Kumari S, Pandey B, Mistry H, Bihani SC, Das A, Prashar V, Gupta GD, Panicker L, Kumar M. J Mol Biol 433 166725 (2021)
  2. Structural biology of SARS-CoV-2 and implications for therapeutic development. Yang H, Rao Z. Nat Rev Microbiol 19 685-700 (2021)
  3. Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis. Ramasamy S, Subbian S. Clin Microbiol Rev 34 e00299-20 (2021)
  4. Type I and III interferon responses in SARS-CoV-2 infection. Kim YM, Shin EC. Exp Mol Med 53 750-760 (2021)
  5. Innate immune sensing of coronavirus and viral evasion strategies. Kasuga Y, Zhu B, Jang KJ, Yoo JS. Exp Mol Med 53 723-736 (2021)
  6. JAK-STAT Pathway Inhibition and their Implications in COVID-19 Therapy. Satarker S, Tom AA, Shaji RA, Alosious A, Luvis M, Nampoothiri M. Postgrad Med 133 489-507 (2021)
  7. Evolutionary trajectory of SARS-CoV-2 and emerging variants. Singh J, Pandit P, McArthur AG, Banerjee A, Mossman K. Virol J 18 166 (2021)
  8. A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic. Triggle CR, Bansal D, Ding H, Islam MM, Farag EABA, Hadi HA, Sultan AA. Front Immunol 12 631139 (2021)
  9. Structural biology of SARS-CoV-2: open the door for novel therapies. Yan W, Zheng Y, Zeng X, He B, Cheng W. Signal Transduct Target Ther 7 26 (2022)
  10. The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19. Schreiber G. Front Immunol 11 595739 (2020)
  11. Ubiquitination in the regulation of inflammatory cell death and cancer. Cockram PE, Kist M, Prakash S, Chen SH, Wertz IE, Vucic D. Cell Death Differ 28 591-605 (2021)
  12. Natural Products, Alone or in Combination with FDA-Approved Drugs, to Treat COVID-19 and Lung Cancer. Yang L, Wang Z. Biomedicines 9 689 (2021)
  13. A critical overview of computational approaches employed for COVID-19 drug discovery. Muratov EN, Amaro R, Andrade CH, Brown N, Ekins S, Fourches D, Isayev O, Kozakov D, Medina-Franco JL, Merz KM, Oprea TI, Poroikov V, Schneider G, Todd MH, Varnek A, Winkler DA, Zakharov AV, Cherkasov A, Tropsha A. Chem Soc Rev 50 9121-9151 (2021)
  14. Mitochondria: In the Cross Fire of SARS-CoV-2 and Immunity. Burtscher J, Cappellano G, Omori A, Koshiba T, Millet GP. iScience 23 101631 (2020)
  15. Overview of SARS-CoV-2 genome-encoded proteins. Bai C, Zhong Q, Gao GF. Sci China Life Sci 65 280-294 (2022)
  16. Mechanisms of Antiviral Immune Evasion of SARS-CoV-2. Beyer DK, Forero A. J Mol Biol 434 167265 (2022)
  17. Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. Zhou YW, Xie Y, Tang LS, Pu D, Zhu YJ, Liu JY, Ma XL. Signal Transduct Target Ther 6 317 (2021)
  18. Role of Host-Mediated Post-Translational Modifications (PTMs) in RNA Virus Pathogenesis. Kumar R, Mehta D, Mishra N, Nayak D, Sunil S. Int J Mol Sci 22 E323 (2020)
  19. Chloroquine and hydroxychloroquine in the treatment of COVID-19: the never-ending story. Gasmi A, Peana M, Noor S, Lysiuk R, Menzel A, Gasmi Benahmed A, Bjørklund G. Appl Microbiol Biotechnol 105 1333-1343 (2021)
  20. Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies. Varghese PM, Tsolaki AG, Yasmin H, Shastri A, Ferluga J, Vatish M, Madan T, Kishore U. Immunobiology 225 152008 (2020)
  21. An update review of emerging small-molecule therapeutic options for COVID-19. Tian D, Liu Y, Liang C, Xin L, Xie X, Zhang D, Wan M, Li H, Fu X, Liu H, Cao W. Biomed Pharmacother 137 111313 (2021)
  22. Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease. Tan H, Hu Y, Jadhav P, Tan B, Wang J. J Med Chem 65 7561-7580 (2022)
  23. An Updated Review of Computer-Aided Drug Design and Its Application to COVID-19. Gurung AB, Ali MA, Lee J, Farah MA, Al-Anazi KM. Biomed Res Int 2021 8853056 (2021)
  24. Immune evasion of SARS-CoV-2 from interferon antiviral system. Min YQ, Huang M, Sun X, Deng F, Wang H, Ning YJ. Comput Struct Biotechnol J 19 4217-4225 (2021)
  25. Innate Immune Response to SARS-CoV-2 Infection: From Cells to Soluble Mediators. Ricci D, Etna MP, Rizzo F, Sandini S, Severa M, Coccia EM. Int J Mol Sci 22 7017 (2021)
  26. Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19. Wu CR, Yin WC, Jiang Y, Xu HE. Acta Pharmacol Sin 43 3021-3033 (2022)
  27. The Ubiquitin-Proteasome System in Immune Cells. Çetin G, Klafack S, Studencka-Turski M, Krüger E, Ebstein F. Biomolecules 11 60 (2021)
  28. The role of death domain proteins in host response upon SARS-CoV-2 infection: modulation of programmed cell death and translational applications. Ivanisenko NV, Seyrek K, Kolchanov NA, Ivanisenko VA, Lavrik IN. Cell Death Discov 6 101 (2020)
  29. Therapeutic strategies for COVID-19: progress and lessons learned. Li G, Hilgenfeld R, Whitley R, De Clercq E. Nat Rev Drug Discov 22 449-475 (2023)
  30. The Role of Epithelial Damage in the Pulmonary Immune Response. Burgoyne RA, Fisher AJ, Borthwick LA. Cells 10 2763 (2021)
  31. Antagonism of Type I Interferon by Severe Acute Respiratory Syndrome Coronavirus 2. Xia H, Shi PY. J Interferon Cytokine Res 40 543-548 (2020)
  32. Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China. Yang L, Wang Z. Eur J Med Chem 257 115503 (2023)
  33. EGCG, a Green Tea Catechin, as a Potential Therapeutic Agent for Symptomatic and Asymptomatic SARS-CoV-2 Infection. Chourasia M, Koppula PR, Battu A, Ouseph MM, Singh AK. Molecules 26 1200 (2021)
  34. Targeting SARS-CoV-2 Proteases for COVID-19 Antiviral Development. Lv Z, Cano KE, Jia L, Drag M, Huang TT, Olsen SK. Front Chem 9 819165 (2021)
  35. Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. Sun C, Xie C, Bu GL, Zhong LY, Zeng MS. Signal Transduct Target Ther 7 202 (2022)
  36. Interferon induction, evasion, and paradoxical roles during SARS-CoV-2 infection. Chiale C, Greene TT, Zuniga EI. Immunol Rev 309 12-24 (2022)
  37. Metal Complexes as Antiviral Agents for SARS-CoV-2. Karges J, Cohen SM. Chembiochem 22 2600-2607 (2021)
  38. Targeting SARS-CoV-2 viral proteases as a therapeutic strategy to treat COVID-19. Anirudhan V, Lee H, Cheng H, Cooper L, Rong L. J Med Virol 93 2722-2734 (2021)
  39. The battle between host and SARS-CoV-2: Innate immunity and viral evasion strategies. Zhang S, Wang L, Cheng G. Mol Ther 30 1869-1884 (2022)
  40. Type I interferons and SARS-CoV-2: from cells to organisms. Bastard P, Zhang Q, Zhang SY, Jouanguy E, Casanova JL. Curr Opin Immunol 74 172-182 (2022)
  41. An overview of potential inhibitors targeting non-structural proteins 3 (PLpro and Mac1) and 5 (3CLpro/Mpro) of SARS-CoV-2. Yan F, Gao F. Comput Struct Biotechnol J 19 4868-4883 (2021)
  42. Phase separation by the SARS-CoV-2 nucleocapsid protein: Consensus and open questions. Cascarina SM, Ross ED. J Biol Chem 298 101677 (2022)
  43. Small molecules in the treatment of COVID-19. Lei S, Chen X, Wu J, Duan X, Men K. Signal Transduct Target Ther 7 387 (2022)
  44. The Functional Deubiquitinating Enzymes in Control of Innate Antiviral Immunity. Zong Z, Zhang Z, Wu L, Zhang L, Zhou F. Adv Sci (Weinh) 8 2002484 (2021)
  45. Host cell-intrinsic innate immune recognition of SARS-CoV-2. Madden EA, Diamond MS. Curr Opin Virol 52 30-38 (2022)
  46. Papain-Like Proteases as Coronaviral Drug Targets: Current Inhibitors, Opportunities, and Limitations. Petushkova AI, Zamyatnin AA. Pharmaceuticals (Basel) 13 E277 (2020)
  47. Antiviral strategies targeting host factors and mechanisms obliging +ssRNA viral pathogens. Mahajan S, Choudhary S, Kumar P, Tomar S. Bioorg Med Chem 46 116356 (2021)
  48. Cell deaths: Involvement in the pathogenesis and intervention therapy of COVID-19. Li X, Zhang Z, Wang Z, Gutiérrez-Castrellón P, Shi H. Signal Transduct Target Ther 7 186 (2022)
  49. Innate immune evasion strategies of SARS-CoV-2. Minkoff JM, tenOever B. Nat Rev Microbiol 21 178-194 (2023)
  50. Natural Products for the Prevention and Control of the COVID-19 Pandemic: Sustainable Bioresources. Singla RK, He X, Chopra H, Tsagkaris C, Shen L, Kamal MA, Shen B. Front Pharmacol 12 758159 (2021)
  51. Transcriptional and Non-Transcriptional Activation, Posttranslational Modifications, and Antiviral Functions of Interferon Regulatory Factor 3 and Viral Antagonism by the SARS-Coronavirus. Glanz A, Chakravarty S, Varghese M, Kottapalli A, Fan S, Chakravarti R, Chattopadhyay S. Viruses 13 575 (2021)
  52. How SARS-CoV-2 (COVID-19) spreads within infected hosts - what we know so far. Sanyal S. Emerg Top Life Sci 4 371-378 (2020)
  53. Interactions between SARS coronavirus 2 papain-like protease and immune system: A potential drug target for the treatment of COVID-19. Mahmoudvand S, Shokri S. Scand J Immunol 94 e13044 (2021)
  54. Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant. Zhou H, Møhlenberg M, Thakor JC, Tuli HS, Wang P, Assaraf YG, Dhama K, Jiang S. Clin Microbiol Rev 35 e0001422 (2022)
  55. Antiviral Drug Discovery for the Treatment of COVID-19 Infections. Ng TI, Correia I, Seagal J, DeGoey DA, Schrimpf MR, Hardee DJ, Noey EL, Kati WM. Viruses 14 961 (2022)
  56. HERC5 and the ISGylation Pathway: Critical Modulators of the Antiviral Immune Response. Mathieu NA, Paparisto E, Barr SD, Spratt DE. Viruses 13 1102 (2021)
  57. SARS-CoV-2 Immuno-Pathogenesis and Potential for Diverse Vaccines and Therapies: Opportunities and Challenges. McGill AR, Kahlil R, Dutta R, Green R, Howell M, Mohapatra S, Mohapatra SS. Infect Dis Rep 13 102-125 (2021)
  58. An expanded lexicon for the ubiquitin code. Dikic I, Schulman BA. Nat Rev Mol Cell Biol 24 273-287 (2023)
  59. Medicinal chemistry strategies towards the development of effective SARS-CoV-2 inhibitors. Gao S, Huang T, Song L, Xu S, Cheng Y, Cherukupalli S, Kang D, Zhao T, Sun L, Zhang J, Zhan P, Liu X. Acta Pharm Sin B 12 581-599 (2022)
  60. Characterization of SARS-CoV-2 Evasion: Interferon Pathway and Therapeutic Options. Znaidia M, Demeret C, van der Werf S, Komarova AV. Viruses 14 1247 (2022)
  61. Interferon antagonists encoded by SARS-CoV-2 at a glance. Lee JH, Koepke L, Kirchhoff F, Sparrer KMJ. Med Microbiol Immunol 212 125-131 (2023)
  62. Methodology-Centered Review of Molecular Modeling, Simulation, and Prediction of SARS-CoV-2. Gao K, Wang R, Chen J, Cheng L, Frishcosy J, Huzumi Y, Qiu Y, Schluckbier T, Wei X, Wei GW. Chem Rev 122 11287-11368 (2022)
  63. Viral Evasion of RIG-I-Like Receptor-Mediated Immunity through Dysregulation of Ubiquitination and ISGylation. Chiang C, Liu G, Gack MU. Viruses 13 182 (2021)
  64. Virus Caused Imbalance of Type I IFN Responses and Inflammation in COVID-19. Zhang J, Zhang J, Zhao C, Zhao W. Front Immunol 12 633769 (2021)
  65. Mega doses of retinol: A possible immunomodulation in Covid-19 illness in resource-limited settings. Midha IK, Kumar N, Kumar A, Madan T. Rev Med Virol 31 1-14 (2021)
  66. Proteomics in the COVID-19 Battlefield: First Semester Check-Up. Grenga L, Armengaud J. Proteomics 21 e2000198 (2021)
  67. The Role of the Host Ubiquitin System in Promoting Replication of Emergent Viruses. Valerdi KM, Hage A, van Tol S, Rajsbaum R, Giraldo MI. Viruses 13 369 (2021)
  68. A Biochemical Perspective of the Nonstructural Proteins (NSPs) and the Spike Protein of SARS CoV-2. Yoshimoto FK. Protein J 40 260-295 (2021)
  69. A structural view of the SARS-CoV-2 virus and its assembly. Hardenbrook NJ, Zhang P. Curr Opin Virol 52 123-134 (2022)
  70. ISGylation in Innate Antiviral Immunity and Pathogen Defense Responses: A Review. Zhang M, Li J, Yan H, Huang J, Wang F, Liu T, Zeng L, Zhou F. Front Cell Dev Biol 9 788410 (2021)
  71. Structure-Function Characteristics of SARS-CoV-2 Proteases and Their Potential Inhibitors from Microbial Sources. Razali R, Asis H, Budiman C. Microorganisms 9 2481 (2021)
  72. An Overview of Current Knowledge of Deadly CoVs and Their Interface with Innate Immunity. Zhang Y, Gargan S, Lu Y, Stevenson NJ. Viruses 13 560 (2021)
  73. Current utilization of interferon alpha for the treatment of coronavirus disease 2019: A comprehensive review. Lu LY, Feng PH, Yu MS, Chen MC, Lin AJ, Chen JL, Yu LH. Cytokine Growth Factor Rev 63 34-43 (2022)
  74. Immunopathology and Immunopathogenesis of COVID-19, what we know and what we should learn. Shahgolzari M, Yavari A, Arjeini Y, Miri SM, Darabi A, Mozaffari Nejad AS, Keshavarz M. Gene Rep 25 101417 (2021)
  75. SARS-CoV-2 variants preferentially emerge at intrinsically disordered protein sites helping immune evasion. Quaglia F, Salladini E, Carraro M, Minervini G, Tosatto SCE, Le Mercier P. FEBS J 289 4240-4250 (2022)
  76. Selenium to selenoproteins - role in COVID-19. Tomo S, Saikiran G, Banerjee M, Paul S. EXCLI J 20 781-791 (2021)
  77. Therapeutic Potential of Glycosyl Flavonoids as Anti-Coronaviral Agents. Godinho PIC, Soengas RG, Silva VLM. Pharmaceuticals (Basel) 14 546 (2021)
  78. An Impaired Inflammatory and Innate Immune Response in COVID-19. Park SH. Mol Cells 44 384-391 (2021)
  79. Phyto-pharmacological perspective of Silymarin: A potential prophylactic or therapeutic agent for COVID-19, based on its promising immunomodulatory, anti-coagulant and anti-viral property. Palit P, Mukhopadhyay A, Chattopadhyay D. Phytother Res 35 4246-4257 (2021)
  80. Proteomics-Based Insights Into the SARS-CoV-2-Mediated COVID-19 Pandemic: A Review of the First Year of Research. Praissman JL, Wells L. Mol Cell Proteomics 20 100103 (2021)
  81. SARS-CoV-2 Non-Structural Proteins and Their Roles in Host Immune Evasion. Low ZY, Zabidi NZ, Yip AJW, Puniyamurti A, Chow VTK, Lal SK. Viruses 14 1991 (2022)
  82. SARS-CoV-2-mediated evasion strategies for antiviral interferon pathways. Oh SJ, Shin OS. J Microbiol 60 290-299 (2022)
  83. Therapeutics for COVID-19. Toussi SS, Hammond JL, Gerstenberger BS, Anderson AS. Nat Microbiol 8 771-786 (2023)
  84. Understanding Individual SARS-CoV-2 Proteins for Targeted Drug Development against COVID-19. van de Leemput J, Han Z. Mol Cell Biol 41 e0018521 (2021)
  85. Disorders of ubiquitylation: unchained inflammation. Beck DB, Werner A, Kastner DL, Aksentijevich I. Nat Rev Rheumatol 18 435-447 (2022)
  86. Infection-induced inflammation from specific inborn errors of immunity to COVID-19. Ku CL, Chen IT, Lai MZ. FEBS J 288 5021-5041 (2021)
  87. Post-Translational Modifications of cGAS-STING: A Critical Switch for Immune Regulation. Yu Y, Liu J, Liu C, Liu R, Liu L, Yu Z, Zhuang J, Sun C. Cells 11 3043 (2022)
  88. Reducing SARS-CoV-2 pathological protein activity with small molecules. Pluskota-Karwatka D, Hoffmann M, Barciszewski J. J Pharm Anal 11 383-397 (2021)
  89. Review Devil's tools: SARS-CoV-2 antagonists against innate immunity. Xu D, Biswal M, Neal A, Hai R. Curr Res Virol Sci 2 100013 (2021)
  90. Role of Virally-Encoded Deubiquitinating Enzymes in Regulation of the Virus Life Cycle. Proulx J, Borgmann K, Park IW. Int J Mol Sci 22 4438 (2021)
  91. Viral Proteases as Targets for Coronavirus Disease 2019 Drug Development. Zhu W, Shyr Z, Lo DC, Zheng W. J Pharmacol Exp Ther 378 166-172 (2021)
  92. Advances in Pathogenesis, Progression, Potential Targets and Targeted Therapeutic Strategies in SARS-CoV-2-Induced COVID-19. Zhou H, Ni WJ, Huang W, Wang Z, Cai M, Sun YC. Front Immunol 13 834942 (2022)
  93. An update on emerging therapeutics to combat COVID-19. Shah NN, Nabi SU, Rather MA, Kalwar Q, Ali SI, Sheikh WM, Ganai A, Bashir SM. Basic Clin Pharmacol Toxicol 129 104-129 (2021)
  94. Impaired innate antiviral defenses in COVID-19: Causes, consequences and therapeutic opportunities. Galani IE, Andreakos E. Semin Immunol 55 101522 (2021)
  95. Innate lymphoid cells (ILC) in SARS-CoV-2 infection. Kumar A, Cao W, Endrias K, Kuchipudi SV, Mittal SK, Sambhara S. Mol Aspects Med 80 101008 (2021)
  96. Molecular Mechanisms of Possible Action of Phenolic Compounds in COVID-19 Protection and Prevention. Gligorijevic N, Radomirovic M, Nedic O, Stojadinovic M, Khulal U, Stanic-Vucinic D, Cirkovic Velickovic T. Int J Mol Sci 22 12385 (2021)
  97. Protease Inhibition-An Established Strategy to Combat Infectious Diseases. Sojka D, Šnebergerová P, Robbertse L. Int J Mol Sci 22 5762 (2021)
  98. Proteomics Mapping of the ISGylation Landscape in Innate Immunity. Thery F, Eggermont D, Impens F. Front Immunol 12 720765 (2021)
  99. Role of phytoconstituents in the management of COVID-19. Das A, Pandita D, Jain GK, Agarwal P, Grewal AS, Khar RK, Lather V. Chem Biol Interact 341 109449 (2021)
  100. SARS-CoV-2-Morphology, Transmission and Diagnosis during Pandemic, Review with Element of Meta-Analysis. Grudlewska-Buda K, Wiktorczyk-Kapischke N, Wałecka-Zacharska E, Kwiecińska-Piróg J, Buszko K, Leis K, Juszczuk K, Gospodarek-Komkowska E, Skowron K. J Clin Med 10 1962 (2021)
  101. A review on computer-aided chemogenomics and drug repositioning for rational COVID-19 drug discovery. Maghsoudi S, Taghavi Shahraki B, Rameh F, Nazarabi M, Fatahi Y, Akhavan O, Rabiee M, Mostafavi E, Lima EC, Saeb MR, Rabiee N. Chem Biol Drug Des 100 699-721 (2022)
  102. An Update on Innate Immune Responses during SARS-CoV-2 Infection. Zhang Y, Chen S, Jin Y, Ji W, Zhang W, Duan G. Viruses 13 2060 (2021)
  103. DrugDevCovid19: An Atlas of Anti-COVID-19 Compounds Derived by Computer-Aided Drug Design. Liu Y, Gan J, Wang R, Yang X, Xiao Z, Cao Y. Molecules 27 683 (2022)
  104. Host ADP-ribosylation and the SARS-CoV-2 macrodomain. Hoch NC. Biochem Soc Trans 49 1711-1721 (2021)
  105. Mechanistic understanding of innate and adaptive immune responses in SARS-CoV-2 infection. Balkhi MY. Mol Immunol 135 268-275 (2021)
  106. SARS-CoV-2 Papain-Like Protease: Structure, Function and Inhibition. Ullrich S, Nitsche C. Chembiochem 23 e202200327 (2022)
  107. Targeting SARS-CoV-2 papain-like protease in the postvaccine era. Ton AT, Pandey M, Smith JR, Ban F, Fernandez M, Cherkasov A. Trends Pharmacol Sci 43 906-919 (2022)
  108. The effects of SARS-CoV-2 infection on modulating innate immunity and strategies of combating inflammatory response for COVID-19 therapy. Wang Y, Wu M, Li Y, Yuen HH, He ML. J Biomed Sci 29 27 (2022)
  109. A Multidisciplinary Approach to Coronavirus Disease (COVID-19). Gediz Erturk A, Sahin A, Bati Ay E, Pelit E, Bagdatli E, Kulu I, Gul M, Mesci S, Eryilmaz S, Oba Ilter S, Yildirim T. Molecules 26 3526 (2021)
  110. Acriflavine, an Acridine Derivative for Biomedical Application: Current State of the Art. Piorecka K, Kurjata J, Stanczyk WA. J Med Chem 65 11415-11432 (2022)
  111. Drug repurposing against SARS-CoV-2 using computational approaches. Kumar S, Kovalenko S, Bhardwaj S, Sethi A, Gorobets NY, Desenko SM, Poonam, Rathi B. Drug Discov Today 27 2015-2027 (2022)
  112. Host and Viral Zinc-Finger Proteins in COVID-19. Esposito S, D'Abrosca G, Antolak A, Pedone PV, Isernia C, Malgieri G. Int J Mol Sci 23 3711 (2022)
  113. Insight into the emerging role of SARS-CoV-2 nonstructural and accessory proteins in modulation of multiple mechanisms of host innate defense. Abdalla AE, Xie J, Junaid K, Younas S, Elsaman T, Abosalif KOA, Alameen AAM, Mahjoob MO, Elamir MYM, Ejaz H. Bosn J Basic Med Sci 21 515-527 (2021)
  114. Precursors of Viral Proteases as Distinct Drug Targets. Majerová T, Novotný P. Viruses 13 1981 (2021)
  115. The deciphering of the immune cells and marker signature in COVID-19 pathogenesis: An update. Jasim SA, Mahdi RS, Bokov DO, Najm MAA, Sobirova GN, Bafoyeva ZO, Taifi A, Alkadir OKA, Mustafa YF, Mirzaei R, Karampoor S. J Med Virol 94 5128-5148 (2022)
  116. Understanding Severe Acute Respiratory Syndrome Coronavirus 2 Replication to Design Efficient Drug Combination Therapies. Ortega JT, Zambrano JL, Jastrzebska B, Liprandi F, Rangel HR, Pujol FH. Intervirology 63 2-9 (2020)
  117. A critical evaluation of risk to reward ratio of quercetin supplementation for COVID-19 and associated comorbid conditions. Pawar A, Russo M, Rani I, Rani I, Goswami K, Russo GL, Pal A. Phytother Res 36 2394-2415 (2022)
  118. Chalcone-amide, a privileged backbone for the design and development of selective SARS-CoV/SARS-CoV-2 papain-like protease inhibitors. Valipour M. Eur J Med Chem 240 114572 (2022)
  119. Functional Contribution and Targeted Migration of Group-2 Innate Lymphoid Cells in Inflammatory Lung Diseases: Being at the Right Place at the Right Time. Wirtz S, Schulz-Kuhnt A, Neurath MF, Atreya I. Front Immunol 12 688879 (2021)
  120. Host Protective Immunity against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and the COVID-19 Vaccine-Induced Immunity against SARS-CoV-2 and Its Variants. Noor R. Viruses 14 2541 (2022)
  121. Innate Immunity Evasion Strategies of Highly Pathogenic Coronaviruses: SARS-CoV, MERS-CoV, and SARS-CoV-2. Li JY, Zhou ZJ, Wang Q, He QN, Zhao MY, Qiu Y, Ge XY. Front Microbiol 12 770656 (2021)
  122. Insights into pandemic respiratory viruses: manipulation of the antiviral interferon response by SARS-CoV-2 and influenza A virus. Liu G, Gack MU. Curr Opin Immunol 78 102252 (2022)
  123. Inter-proteomic posttranslational modifications of the SARS-CoV-2 and the host proteins ‒ A new frontier. Mishra S, Bassi G, Nyomba BG. Exp Biol Med (Maywood) 246 749-757 (2021)
  124. Nuclear Medicine in Times of COVID-19: How Radiopharmaceuticals Could Help to Fight the Current and Future Pandemics. Neumaier F, Zlatopolskiy BD, Neumaier B. Pharmaceutics 12 E1247 (2020)
  125. Recent advances in small-molecular therapeutics for COVID-19. Zhong L, Zhao Z, Peng X, Zou J, Yang S. Precis Clin Med 5 pbac024 (2022)
  126. Structural biology in the time of COVID-19: perspectives on methods and milestones. Lynch ML, Snell EH, Bowman SEJ. IUCrJ 8 335-341 (2021)
  127. Structural insights of key enzymes into therapeutic intervention against SARS-CoV-2. Shahid M, Shahzad-Ul-Hussan S. J Struct Biol 213 107690 (2021)
  128. A Review of Extracellular Vesicles in COVID-19 Diagnosis, Treatment, and Prevention. Su P, Wu Y, Xie F, Zheng Q, Chen L, Liu Z, Meng X, Zhou F, Zhang L. Adv Sci (Weinh) 10 e2206095 (2023)
  129. Coronaviral PLpro proteases and the immunomodulatory roles of conjugated versus free Interferon Stimulated Gene product-15 (ISG15). Gold IM, Reis N, Glaser F, Glickman MH. Semin Cell Dev Biol 132 16-26 (2022)
  130. Deciphering Respiratory-Virus-Associated Interferon Signaling in COPD Airway Epithelium. Guo-Parke H, Linden D, Weldon S, Kidney JC, Taggart CC. Medicina (Kaunas) 58 121 (2022)
  131. Imaging and visualizing SARS-CoV-2 in a new era for structural biology. Leigh KE, Modis Y. Interface Focus 11 20210019 (2021)
  132. Molecular Insights of SARS-CoV-2 Antivirals Administration: A Balance between Safety Profiles and Impact on Cardiovascular Phenotypes. Nappi F, Iervolino A, Avtaar Singh SS. Biomedicines 10 437 (2022)
  133. Multivalent ACE2 engineering-A promising pathway for advanced coronavirus nanomedicine development. Obeng EM, Fianu I, Danquah MK. Nano Today 46 101580 (2022)
  134. Pharmacotherapeutics of SARS-CoV-2 Infections. Kevadiya BD, Machhi J, Herskovitz J, Oleynikov MD, Blomberg WR, Bajwa N, Soni D, Das S, Hasan M, Patel M, Senan AM, Gorantla S, McMillan J, Edagwa B, Eisenberg R, Gurumurthy CB, Reid SPM, Punyadeera C, Chang L, Gendelman HE. J Neuroimmune Pharmacol 16 12-37 (2021)
  135. Structural insights into SARS-CoV-2 infection and therapeutics development. Sun G, Xue L, He Q, Zhao Y, Xu W, Wang Z. Stem Cell Res 52 102219 (2021)
  136. Targeting the Ubiquitylation and ISGylation Machinery for the Treatment of COVID-19. Vere G, Alam MR, Farrar S, Kealy R, Kessler BM, O'Brien DP, Pinto-Fernández A. Biomolecules 12 300 (2022)
  137. The Regulatory Network of Cyclic GMP-AMP Synthase-Stimulator of Interferon Genes Pathway in Viral Evasion. Hu T, Pan M, Yin Y, Wang C, Cui Y, Wang Q. Front Microbiol 12 790714 (2021)
  138. The Role of Antibodies in the Treatment of SARS-CoV-2 Virus Infection, and Evaluating Their Contribution to Antibody-Dependent Enhancement of Infection. Farouq MAH, Acevedo R, Ferro VA, Mulheran PA, Al Qaraghuli MM. Int J Mol Sci 23 6078 (2022)
  139. The Role of Deubiquitinases in Virus Replication and Host Innate Immune Response. Zhang Q, Jia Q, Gao W, Zhang W. Front Microbiol 13 839624 (2022)
  140. Therapeutic potential of green tea catechin, (-)-epigallocatechin-3-O-gallate (EGCG) in SARS-CoV-2 infection: Major interactions with host/virus proteases. Dinda B, Dinda S, Dinda M. Phytomed Plus 3 100402 (2023)
  141. Type-I interferons in the immunopathogenesis and treatment of Coronavirus disease 2019. Khorramdelazad H, Kazemi MH, Azimi M, Aghamajidi A, Mehrabadi AZ, Shahba F, Aghamohammadi N, Falak R, Faraji F, Jafari R. Eur J Pharmacol 927 175051 (2022)
  142. Biology and Pathogenesis of SARS-CoV-2: Understandings for Therapeutic Developments against COVID-19. Sharma HN, Latimore COD, Matthews QL. Pathogens 10 1218 (2021)
  143. Biomolecular interactions with nanoparticles: applications for coronavirus disease 2019. Farouq MAH, Al Qaraghuli MM, Kubiak-Ossowska K, Ferro VA, Mulheran PA. Curr Opin Colloid Interface Sci 54 101461 (2021)
  144. Coordinated regulation of interferon and inflammasome signaling pathways by SARS-CoV-2 proteins. Kim NE, Song YJ. J Microbiol 60 300-307 (2022)
  145. Coronaviral Infection and Interferon Response: The Virus-Host Arms Race and COVID-19. Liu Q, Chi S, Dmytruk K, Dmytruk O, Tan S. Viruses 14 1349 (2022)
  146. Luciferase-Based Biosensors in the Era of the COVID-19 Pandemic. Azad T, Janse van Rensburg HJ, Morgan J, Rezaei R, Crupi MJF, Chen R, Ghahremani M, Jamalkhah M, Forbes N, Ilkow C, Bell JC. ACS Nanosci Au 1 15-37 (2021)
  147. Novel antiviral effects of chloroquine, hydroxychloroquine, and green tea catechins against SARS CoV-2 main protease (Mpro) and 3C-like protease for COVID-19 treatment. Shaik FB, Swarnalatha K, Mohan MC, Thomas A, Chikati R, Sandeep G, Maddu N. Clin Nutr Open Sci 42 62-72 (2022)
  148. SARS-CoV-2 and the Nucleus. Chen M, Ma Y, Chang W. Int J Biol Sci 18 4731-4743 (2022)
  149. Significance of Immune Status of SARS-CoV-2 Infected Patients in Determining the Efficacy of Therapeutic Interventions. Saratale GD, Shin HS, Shinde SK, Kim DY, Saratale RG, Kadam AA, Kumar M, Bahkali AH, Syed A, Ghodake GS. J Pers Med 12 349 (2022)
  150. The Evolutionary Dance between Innate Host Antiviral Pathways and SARS-CoV-2. Aliyari SR, Quanquin N, Pernet O, Zhang S, Wang L, Cheng G. Pathogens 11 538 (2022)
  151. The role of multi-omics in the diagnosis of COVID-19 and the prediction of new therapeutic targets. Ma J, Deng Y, Zhang M, Yu J. Virulence 13 1101-1110 (2022)
  152. Through DNA sensors and hidden mitochondrial effects of SARS-CoV-2. Targhetta VP, Amaral MA, Camara NOS. J Venom Anim Toxins Incl Trop Dis 27 e20200183 (2021)
  153. Viral proteases as therapeutic targets. Majerová T, Konvalinka J. Mol Aspects Med 88 101159 (2022)
  154. Accelerating antiviral drug discovery: lessons from COVID-19. von Delft A, Hall MD, Kwong AD, Purcell LA, Saikatendu KS, Schmitz U, Tallarico JA, Lee AA. Nat Rev Drug Discov 22 585-603 (2023)
  155. COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy. Khaledi M, Sameni F, Yahyazade S, Radandish M, Owlia P, Bagheri N, Afkhami H, Mahjoor M, Esmaelpour Z, Kohansal M, Aghaei F. Front Med (Lausanne) 9 961027 (2022)
  156. COVID-19 signalome: Potential therapeutic interventions. Lundstrom K, Hromić-Jahjefendić A, Bilajac E, Aljabali AAA, Baralić K, Sabri NA, Shehata EM, Raslan M, Raslan SA, Ferreira ACBH, Orlandi L, Serrano-Aroca Á, Uversky VN, Hassan SS, Redwan EM, Azevedo V, Alzahrani KJ, Alsharif KF, Halawani IF, Alzahrani FM, Tambuwala MM, Barh D. Cell Signal 103 110559 (2023)
  157. Computational anti-COVID-19 drug design: progress and challenges. Wang J, Zhang Y, Nie W, Luo Y, Deng L. Brief Bioinform 23 bbab484 (2022)
  158. Control of Innate Immune Activation by Severe Acute Respiratory Syndrome Coronavirus 2 and Other Coronaviruses. Kehrer T, García-Sastre A, Miorin L. J Interferon Cytokine Res 41 205-219 (2021)
  159. Delineating the SARS-CoV-2 Induced Interplay between the Host Immune System and the DNA Damage Response Network. Papanikolaou C, Rapti V, Stellas D, Stefanou DT, Syrigos K, Pavlakis GN, Souliotis VL. Vaccines (Basel) 10 1764 (2022)
  160. Druggable targets and therapeutic development for COVID-19. Duan X, Lacko LA, Chen S. Front Chem 10 963701 (2022)
  161. Dysregulation of Protein S in COVID-19. Sim MMS, Wood JP. Best Pract Res Clin Haematol 35 101376 (2022)
  162. Interferon at the crossroads of SARS-CoV-2 infection and COVID-19 disease. Samuel CE. J Biol Chem 299 104960 (2023)
  163. Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics. Pavan M, Moro S. Int J Mol Sci 24 4401 (2023)
  164. Mechanisms of Viral Degradation of Cellular Signal Transducer and Activator of Transcription 2. Barik S. Int J Mol Sci 23 489 (2022)
  165. Pathogenic Mechanism and Multi-omics Analysis of Oral Manifestations in COVID-19. Hao M, Wang D, Xia Q, Kan S, Chang L, Liu H, Yang Z, Liu W. Front Immunol 13 879792 (2022)
  166. SARS-CoV-2 and the host-immune response. Maison DP, Deng Y, Gerschenson M. Front Immunol 14 1195871 (2023)
  167. Surgical Strikes on Host Defenses: Role of the Viral Protease Activity in Innate Immune Antagonism. Chin CV, Saeed M. Pathogens 11 522 (2022)
  168. The Pathogenic Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Possible Mechanisms for Immune Evasion? Wang Z, Zhou M, Fu Z, Zhao L. Front Immunol 12 693579 (2021)
  169. The effect of various compounds on the COVID mechanisms, from chemical to molecular aspects. Mahmoudi S, Dehkordi MM, Asgarshamsi MH. Biophys Chem 288 106824 (2022)
  170. The origins of COVID-19 pandemic: A brief overview. Hao YJ, Wang YL, Wang MY, Zhou L, Shi JY, Cao JM, Wang DP. Transbound Emerg Dis 69 3181-3197 (2022)
  171. Uncovering Novel Viral Innate Immune Evasion Strategies: What Has SARS-CoV-2 Taught Us? Tay DJW, Lew ZZR, Chu JJH, Tan KS. Front Microbiol 13 844447 (2022)
  172. Viral evasion of the interferon response at a glance. Zhu J, Chiang C, Gack MU. J Cell Sci 136 jcs260682 (2023)
  173. A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease. Rieder AS, Deniz BF, Netto CA, Wyse ATS. Neurotox Res 40 1553-1569 (2022)
  174. A hypothesis on designing strategy of effective RdRp inhibitors for the treatment of SARS-CoV-2. Chaube U, Patel BD, Bhatt HG. 3 Biotech 13 12 (2023)
  175. A review on computational approaches that support the researches on traditional Chinese medicines (TCM) against COVID-19. Ruchawapol C, Fu WW, Xu HX. Phytomedicine 104 154324 (2022)
  176. Can Probiotics, Particularly Limosilactobacillus fermentum UCO-979C and Lacticaseibacillus rhamnosus UCO-25A, Be Preventive Alternatives against SARS-CoV-2? Valdebenito-Navarrete H, Fuentes-Barrera V, Smith CT, Salas-Burgos A, Zuniga FA, Gomez LA, García-Cancino A. Biology (Basel) 12 384 (2023)
  177. Cellular Deubiquitylating Enzyme: A Regulatory Factor of Antiviral Innate Immunity. Long S, Yang L, Dang W, Xin S, Jiang M, Zhang W, Li J, Wang Y, Zhang S, Lu J. Front Microbiol 12 805223 (2021)
  178. Cellular Sensors and Viral Countermeasures: A Molecular Arms Race between Host and SARS-CoV-2. Sun H, Chan JF, Yuan S. Viruses 15 352 (2023)
  179. Critical Review of Plant-Derived Compounds as Possible Inhibitors of SARS-CoV-2 Proteases: A Comparison with Experimentally Validated Molecules. Guerra Y, Celi D, Cueva P, Perez-Castillo Y, Giampieri F, Alvarez-Suarez JM, Tejera E. ACS Omega 7 44542-44555 (2022)
  180. Deubiquitylating Enzymes in Cancer and Immunity. Ren J, Yu P, Liu S, Li R, Niu X, Chen Y, Zhang Z, Zhou F, Zhang L. Adv Sci (Weinh) 10 e2303807 (2023)
  181. Distinct Molecular Mechanisms Characterizing Pathogenesis of SARS-CoV-2. Lee SJ, Kim YJ, Ahn DG. J Microbiol Biotechnol 32 1073-1085 (2022)
  182. Improved understanding of biorisk for research involving microbial modification using annotated sequences of concern. Godbold GD, Hewitt FC, Kappell AD, Scholz MB, Agar SL, Treangen TJ, Ternus KL, Sandbrink JB, Koblentz GD. Front Bioeng Biotechnol 11 1124100 (2023)
  183. Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19. Valenzuela-Fernández A, Cabrera-Rodriguez R, Ciuffreda L, Perez-Yanes S, Estevez-Herrera J, González-Montelongo R, Alcoba-Florez J, Trujillo-González R, García-Martínez de Artola D, Gil-Campesino H, Díez-Gil O, Lorenzo-Salazar JM, Flores C, Garcia-Luis J. Front Bioeng Biotechnol 10 1052436 (2022)
  184. SARS-CoV-2 Spike-Mediated Entry and Its Regulation by Host Innate Immunity. Yu S, Hu H, Ai Q, Bai R, Ma K, Zhou M, Wang S. Viruses 15 639 (2023)
  185. The current state of validated small molecules inhibiting SARS-CoV-2 nonstructural proteins. Kocabaş F, Uslu M. Turk J Biol 45 469-483 (2021)
  186. A review on in silico virtual screening methods in COVID-19 using anticancer drugs and other natural/chemical inhibitors. Sokouti B. Explor Target Antitumor Ther 4 994-1026 (2023)
  187. Evaluating the Virology and Evolution of Seasonal Human Coronaviruses Associated with the Common Cold in the COVID-19 Era. Harrison CM, Doster JM, Landwehr EH, Kumar NP, White EJ, Beachboard DC, Stobart CC. Microorganisms 11 445 (2023)
  188. Evolution of Sequence and Structure of SARS-CoV-2 Spike Protein: A Dynamic Perspective. Sinha A, Sangeet S, Roy S. ACS Omega 8 23283-23304 (2023)
  189. Forces Driving a Magic Bullet to Its Target: Revisiting the Role of Thermodynamics in Drug Design, Development, and Optimization. Minetti CA, Remeta DP. Life (Basel) 12 1438 (2022)
  190. Harnessing the Power of Venomous Animal-Derived Toxins against COVID-19. Oliveira I, Ferreira I, Jacob B, Cardenas K, Cerni F, Baia-da-Silva D, Arantes E, Monteiro W, Pucca M. Toxins (Basel) 15 159 (2023)
  191. Highlights on molecular targets in the management of COVID-19: Possible role of pharmacogenomics. Thabet RH, Massadeh NA, Badarna OB, Al-Momani OM. J Int Med Res 51 3000605231153764 (2023)
  192. Immunopathological events surrounding IL-6 and IFN-α: A bridge for anti-lupus erythematosus drugs used to treat COVID-19. Zhou B, Li S, Ye J, Liu Y, Hu L, Tang Y, Wu Z, Zhang P. Int Immunopharmacol 101 108254 (2021)
  193. Main and papain-like proteases as prospective targets for pharmacological treatment of coronavirus SARS-CoV-2. Yevsieieva LV, Lohachova KO, Kyrychenko A, Kovalenko SM, Ivanov VV, Kalugin ON. RSC Adv 13 35500-35524 (2023)
  194. Mechanisms of impairment of interferon production by SARS-CoV-2. Hoang HD, Naeli P, Alain T, Jafarnejad SM. Biochem Soc Trans 51 1047-1056 (2023)
  195. Metallo-antiviral aspirants: Answer to the upcoming virus outbreak. Mehrotra R, Shukla SN, Gaur P. Eur J Med Chem Rep 8 100104 (2023)
  196. New insights for infection mechanism and potential targets of COVID-19: Three Chinese patent medicines and three Chinese medicine formulas as promising therapeutic approaches. Jia K, Li Y, Liu T, Gu X, Li X. Chin Herb Med 15 157-168 (2023)
  197. Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS-CoV-2. Xue Y, Mei H, Chen Y, Griffin JD, Liu Q, Weisberg E, Yang J. MedComm (2020) 4 e254 (2023)
  198. Role of E3 ubiquitin ligases and deubiquitinating enzymes in SARS-CoV-2 infection. Zhao M, Zhang M, Yang Z, Zhou Z, Huang J, Zhao B. Front Cell Infect Microbiol 13 1217383 (2023)
  199. SARS-CoV-2 Evasion of the Interferon System: Can We Restore Its Effectiveness? Sacchi A, Giannessi F, Sabatini A, Percario ZA, Affabris E. Int J Mol Sci 24 9353 (2023)
  200. SARS-CoV-2 and innate immunity: the good, the bad, and the "goldilocks". Sievers BL, Cheng MTK, Csiba K, Meng B, Gupta RK. Cell Mol Immunol (2023)
  201. SARS-CoV-2 biology and host interactions. Steiner S, Kratzel A, Barut GT, Lang RM, Aguiar Moreira E, Thomann L, Kelly JN, Thiel V. Nat Rev Microbiol (2024)
  202. SARS-CoV-PLpro-Inhibitoren als mögliche Breitspektrum-Virostatika. Hammerschmidt SJ, Müller P, Schirmeister T. Biospektrum (Heidelb) 27 254-256 (2021)
  203. Significant perspectives on various viral infections targeted antiviral drugs and vaccines including COVID-19 pandemicity. Arumugam GS, Damodharan K, Doble M, Thennarasu S. Mol Biomed 3 21 (2022)
  204. Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period. Ao D, He X, Liu J, Xu L. Signal Transduct Target Ther 8 466 (2023)
  205. Structural and non-structural proteins in SARS-CoV-2: potential aspects to COVID-19 treatment or prevention of progression of related diseases. Kakavandi S, Zare I, VaezJalali M, Dadashi M, Azarian M, Akbari A, Ramezani Farani M, Zalpoor H, Hajikhani B. Cell Commun Signal 21 110 (2023)
  206. Targeting SARS-CoV-2 Non-Structural Proteins. Tam D, Lorenzo-Leal AC, Hernández LR, Bach H. Int J Mol Sci 24 13002 (2023)
  207. Targeting the Ubiquitin-Proteasome System and Recent Advances in Cancer Therapy. Spano D, Catara G. Cells 13 29 (2023)
  208. Ubiquitin-Dependent and Independent Proteasomal Degradation in Host-Pathogen Interactions. Bialek W, Collawn JF, Bartoszewski R. Molecules 28 6740 (2023)
  209. What do we know about the function of SARS-CoV-2 proteins? Justo Arevalo S, Castillo-Chávez A, Uribe Calampa CS, Zapata Sifuentes D, Huallpa CJ, Landa Bianchi G, Garavito-Salini Casas R, Quiñones Aguilar M, Pineda Chavarría R. Front Immunol 14 1249607 (2023)
  210. [Interaction between SARS-CoV-2 and Host Innate Immunity]. Duan XQ, Xie H, Chen LM. Sichuan Da Xue Xue Bao Yi Xue Ban 53 1-6 (2022)

Articles citing this publication (286)



Related citations provided by authors (1)

Quick links